Interferon beta gene therapy - Biogen Idec/Targeted Genetics

Drug Profile

Interferon beta gene therapy - Biogen Idec/Targeted Genetics

Alternative Names: Ad-beta-Ifn; Beta-interferon gene therapy - Biogen Idec/Targeted Genetics; BG 00001; IDEC-201

Latest Information Update: 05 Mar 2008

Price : $50

At a glance

  • Originator Biogen Idec; Targeted Genetics
  • Developer Biogen Idec; Targeted Genetics Corporation
  • Class Antivirals; Cytokine genes; Gene therapies; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glioblastoma

Most Recent Events

  • 24 Jun 2005 Data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the Cancer pharmacodynamics section
  • 03 Mar 2004 A preclinical study has been added to the Cancer pharmacodynamics section
  • 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top